Suzie Siegel: A comprehensive report on leiomyosarcoma

Suzie Siegel, Newspaper reporter and editor at LMS papers, shared a post on X/Twitter:

“This is a comprehensive report on leiomyosarcoma from Elise Nassif, Emily Keung, Michael Nakazawa, Amanda Dann, Ryan Denu. Among other ideas, they see clinical trials as a good way to tease apart which of the 3 LMS subtypes respond to which drugs.

Additional work is needed to identify and implement pharmacogenomic biomarkers into current clinical practice in LMS, as well as undertake these types of biomarker analyses in future drug development studies.

The use of aromatase inhibitors in uterine leiomyosarcoma continues to be a hot topic among patients. The MD Anderson Cancer Center review says: “The success of these hormone therapies has been limited, the quality of data supporting them is low …”.

And these agents are falling out of favor, particularly at sarcoma centers. Nevertheless, there may be some role for these treatments in low-grade ULMS.”

View additional information.
Source: Suzie Siegel/X